D.E. Shaw & Co
ATNM icon

D.E. Shaw & Co’s Actinium Pharmaceuticals ATNM Stock Holding History

D.E. Shaw & Co’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,337
Closed -$217K – 4523
2024
Q2 		$217K Buy
+29,337
New +$242K ﹤0.01% 4047
2023
Q4 		– Sell
-18,002
Closed -$107K – 4311
2023
Q3 		$107K Sell
18,002
-10,752
-37% -$71.5K ﹤0.01% 3847
2023
Q2 		$213K Sell
28,754
-12,144
-30% -$103K ﹤0.01% 3719
2023
Q1 		$386K Sell
40,898
-236,222
-85% -$2.49M ﹤0.01% 3660
2022
Q4 		$2.95M Buy
277,120
+239,196
+631% +$2.43M ﹤0.01% 2609
2022
Q3 		$280K Buy
37,924
+20,600
+119% +$128K ﹤0.01% 4328
2022
Q2 		$83K Sell
17,324
-5,711
-25% -$32.4K ﹤0.01% 4764
2022
Q1 		$118K Sell
23,035
-2,438
-10% -$12.8K ﹤0.01% 4974
2021
Q4 		$153K Sell
25,473
-2,646
-9% -$19.9K ﹤0.01% 4959
2021
Q3 		$249K Buy
+28,119
New +$196K ﹤0.01% 4461
2021
Q1 		– Sell
-64,181
Closed -$501K – 4030
2020
Q4 		$501K Buy
+64,181
New +$697K ﹤0.01% 3387

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

D.E. Shaw & Co's ATNM Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 29,337 shares — an estimated $217K sold.

D.E. Shaw & Co first reported a position in ATNM in Q4 2020 and held it in 11 quarters. The position peaked at $2.95M in Q4 2022. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 29,337 Actinium Pharmaceuticals shares in Q3 2024, an estimated $217K.
  • D.E. Shaw & Co first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • D.E. Shaw & Co's Actinium Pharmaceuticals position peaked at $2.95M in Q4 2022.
  • 72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.